AIDS: A study of the experimental anti-cytomegalovirus (CMV) drug, MSL-109 manufactured by Protein Design Labs, was halted after an interim analysis found that the treatment offered no benefit over placebo, and that more deaths appeared to occur among patients receiving the drug. Two other large MSL-109 studies are still ongoing. One study, a CMV prophylaxis study in bone marrow transplant patients, is continuing due to lack of abnormal mortality or side effects being reported. Another study conducted by ACTG, study #266, has been placed on temporary hold.